QQQ   382.55 (+1.22%)
AAPL   149.40 (+0.51%)
MSFT   310.32 (+0.71%)
FB   322.12 (-2.00%)
GOOGL   2,774.21 (+0.92%)
TSLA   1,093.23 (+6.67%)
AMZN   3,412.42 (+2.77%)
NVDA   250.99 (+8.34%)
BABA   172.03 (-2.35%)
NIO   41.99 (+1.74%)
CGC   13.54 (-0.22%)
GE   107.82 (+2.39%)
AMD   126.05 (+3.02%)
MU   69.17 (+0.60%)
T   25.59 (-0.20%)
F   15.99 (-0.06%)
ACB   7.12 (-0.84%)
DIS   172.92 (+0.53%)
PFE   43.28 (+0.30%)
BA   213.28 (+0.19%)
AMC   36.36 (-1.28%)
QQQ   382.55 (+1.22%)
AAPL   149.40 (+0.51%)
MSFT   310.32 (+0.71%)
FB   322.12 (-2.00%)
GOOGL   2,774.21 (+0.92%)
TSLA   1,093.23 (+6.67%)
AMZN   3,412.42 (+2.77%)
NVDA   250.99 (+8.34%)
BABA   172.03 (-2.35%)
NIO   41.99 (+1.74%)
CGC   13.54 (-0.22%)
GE   107.82 (+2.39%)
AMD   126.05 (+3.02%)
MU   69.17 (+0.60%)
T   25.59 (-0.20%)
F   15.99 (-0.06%)
ACB   7.12 (-0.84%)
DIS   172.92 (+0.53%)
PFE   43.28 (+0.30%)
BA   213.28 (+0.19%)
AMC   36.36 (-1.28%)
QQQ   382.55 (+1.22%)
AAPL   149.40 (+0.51%)
MSFT   310.32 (+0.71%)
FB   322.12 (-2.00%)
GOOGL   2,774.21 (+0.92%)
TSLA   1,093.23 (+6.67%)
AMZN   3,412.42 (+2.77%)
NVDA   250.99 (+8.34%)
BABA   172.03 (-2.35%)
NIO   41.99 (+1.74%)
CGC   13.54 (-0.22%)
GE   107.82 (+2.39%)
AMD   126.05 (+3.02%)
MU   69.17 (+0.60%)
T   25.59 (-0.20%)
F   15.99 (-0.06%)
ACB   7.12 (-0.84%)
DIS   172.92 (+0.53%)
PFE   43.28 (+0.30%)
BA   213.28 (+0.19%)
AMC   36.36 (-1.28%)
QQQ   382.55 (+1.22%)
AAPL   149.40 (+0.51%)
MSFT   310.32 (+0.71%)
FB   322.12 (-2.00%)
GOOGL   2,774.21 (+0.92%)
TSLA   1,093.23 (+6.67%)
AMZN   3,412.42 (+2.77%)
NVDA   250.99 (+8.34%)
BABA   172.03 (-2.35%)
NIO   41.99 (+1.74%)
CGC   13.54 (-0.22%)
GE   107.82 (+2.39%)
AMD   126.05 (+3.02%)
MU   69.17 (+0.60%)
T   25.59 (-0.20%)
F   15.99 (-0.06%)
ACB   7.12 (-0.84%)
DIS   172.92 (+0.53%)
PFE   43.28 (+0.30%)
BA   213.28 (+0.19%)
AMC   36.36 (-1.28%)
NASDAQ:ELGX

Endologix Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.02
$0.22
52-Week Range N/A
VolumeN/A
Average Volume1.28 million shs
Market Capitalization$382,000.00
P/E RatioN/A
Dividend YieldN/A
Beta0.73

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Endologix and its competitors with MarketBeat's FREE daily newsletter.


Endologix logo

About Endologix

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Headlines

Endologix buys PQ Bypass - Phoenix Business Journal
April 19, 2021 |  bizjournals.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ELGX
CUSIP
29266S10
Employees
528
Year Founded
N/A

Sales & Book Value

Annual Sales
$143.37 million
Book Value
$3.56 per share

Profitability

Net Income
$-64.76 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$382,000.00
Next Earnings Date
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

1.17 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Endologix (NASDAQ:ELGX) Frequently Asked Questions

What stocks does MarketBeat like better than Endologix?

Wall Street analysts have given Endologix a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Endologix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings data on Monday, May, 11th. The medical instruments supplier reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.13. The medical instruments supplier earned $28.51 million during the quarter, compared to analyst estimates of $28.50 million. Endologix had a negative net margin of 44.65% and a negative trailing twelve-month return on equity of 63.96%.
View Endologix's earnings history
.

When did Endologix's stock split? How did Endologix's stock split work?

Endologix's stock reverse split before market open on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

Who are Endologix's key executives?

Endologix's management team includes the following people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

What other stocks do shareholders of Endologix own?

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How much money does Endologix make?

Endologix has a market capitalization of $0.00 and generates $143.37 million in revenue each year. The medical instruments supplier earns $-64.76 million in net income (profit) each year or ($2.19) on an earnings per share basis.

How many employees does Endologix have?

Endologix employs 528 workers across the globe.

What is Endologix's official website?

The official website for Endologix is www.endologix.com.

Where are Endologix's headquarters?

Endologix is headquartered at 2 MUSICK, IRVINE CA, 92618.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected].


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.